These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19025125)

  • 21. Use of complement inhibitors in tissue injury.
    Quigg RJ
    Trends Mol Med; 2002 Sep; 8(9):430-6. PubMed ID: 12223314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement evasion by human pathogens.
    Lambris JD; Ricklin D; Geisbrecht BV
    Nat Rev Microbiol; 2008 Feb; 6(2):132-42. PubMed ID: 18197169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease.
    Barnum SR
    Mol Med; 1999 Sep; 5(9):569-82. PubMed ID: 10551898
    [No Abstract]   [Full Text] [Related]  

  • 24. Alternative complement activity in the egg cytosol of amphioxus Branchiostoma belcheri: evidence for the defense role of maternal complement components.
    Liang Y; Zhang S; Wang Z
    PLoS One; 2009; 4(1):e4234. PubMed ID: 19156196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nephritic factor, C3 splitting activity, C3 and factor B breakdown products in glomerular diseases.
    De Vecchi A; Montagnino G; Scalia P; Tarantino A
    Ric Clin Lab; 1980; 10(1):93-7. PubMed ID: 6781054
    [No Abstract]   [Full Text] [Related]  

  • 26. Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications.
    Heesterbeek DAC; Angelier ML; Harrison RA; Rooijakkers SHM
    J Innate Immun; 2018; 10(5-6):455-464. PubMed ID: 30149378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitors of the complement system currently in development for cardiovascular disease.
    Pugsley MK; Abramova M; Cole T; Yang X; Ammons WS
    Cardiovasc Toxicol; 2003; 3(1):43-70. PubMed ID: 12668890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Role of membrane molecules in complement system].
    Okada N
    Rinsho Byori; 1991 Sep; Suppl 91():129-39. PubMed ID: 1721938
    [No Abstract]   [Full Text] [Related]  

  • 29. Therapeutic inhibition of the early phase of complement activation.
    Roos A; Ramwadhdoebé TH; Nauta AJ; Hack CE; Daha MR
    Immunobiology; 2002 Sep; 205(4-5):595-609. PubMed ID: 12396018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complement activation following oxidative stress.
    Collard CD; Lekowski R; Jordan JE; Agah A; Stahl GL
    Mol Immunol; 1999; 36(13-14):941-8. PubMed ID: 10698348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory effect of FUT-175 on complement activation and its application for glomerulonephritis with hypocomplementemia.
    Fujita Y; Inoue I; Inagi R; Miyata T; Shinzato T; Sugiyama S; Miyama A; Maeda K
    Nihon Jinzo Gakkai Shi; 1993 Apr; 35(4):393-7. PubMed ID: 8341019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological manipulation of the complement system in human diseases.
    Asghar SS
    Front Biosci; 1996 Mar; 1():e15-25. PubMed ID: 9159241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunization against tumor cell surface complement-regulatory proteins.
    Durrant LG; Spendlove I
    Curr Opin Investig Drugs; 2001 Jul; 2(7):959-66. PubMed ID: 11757799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent developments in low molecular weight complement inhibitors.
    Qu H; Ricklin D; Lambris JD
    Mol Immunol; 2009 Dec; 47(2-3):185-95. PubMed ID: 19800693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement.
    Verbrugh HA; Peterson PK; Nguyen BY; Sisson SP; Kim Y
    J Immunol; 1982 Oct; 129(4):1681-7. PubMed ID: 7108223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Learnings from over 25 years of PNH experience: the era of targeted complement inhibition.
    Heitlinger E
    Blood Rev; 2013 Dec; 27 Suppl 1():S1-6. PubMed ID: 24331206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones.
    Chen S; Caragine T; Cheung NK; Tomlinson S
    Am J Pathol; 2000 Mar; 156(3):1085-91. PubMed ID: 10702424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction?
    Nijmeijer R; Lagrand WK; Visser CA; Meijer CJ; Niessen HW; Hack CE
    Int Immunopharmacol; 2001 Mar; 1(3):403-14. PubMed ID: 11367525
    [No Abstract]   [Full Text] [Related]  

  • 39. [Complement and bio-phylaxis].
    Nihon Rinsho; 1990 Jul; 48 Suppl():342-440. PubMed ID: 2214200
    [No Abstract]   [Full Text] [Related]  

  • 40. Therapeutic potential of targeting the complement cascade in critical care medicine.
    Bhole D; Stahl GL
    Crit Care Med; 2003 Jan; 31(1 Suppl):S97-104. PubMed ID: 12544983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.